AstraZeneca results: 9M and Q3 2026
Key takeaways
- AstraZeneca’s 9‑month 2026 results show solid revenue and earnings growth, new drug approvals, and a strong pipeline, underpinning its 2030 growth targets.
- Total revenue 46.9 billion (+7%)
- Core 8.00 (+14%)
EPS
Earnings per share — profit for one share of the company, in dollars.
- 47 new approvals
What happened
AstraZeneca reported its first nine months of 2026 results, showing total revenue up 7% to $46.9 billion and core earnings per share up 14% to $8.00. The company highlighted double‑digit growth in oncology, research and innovation (R&I), and rare disease, while noting headwinds from the loss of exclusivity on Farxiga and Brilinta and volume‑based procurement in China. It announced 47 new drug approvals worldwide, including four first‑time approvals for Etcamah, Baxfendy, Klygefa and Amlypave,…
Why it matters
The results confirm AstraZeneca’s ability to sustain growth across its core therapeutic areas and demonstrate a robust pipeline with significant commercial potential. The 7% revenue rise and 14% core Earnings per share — profit for one share of the company, in dollars.EPS
Short-term and longer-term
Short-term. Over the next few days, traders should watch for the release of the Q3 2026 earnings call and any updates on the Phase III readouts.
Longer-term. For investors, the 9‑month results reinforce AstraZeneca’s long‑term growth narrative, with a pipeline that could add significant revenue in the coming years.
Words on this card
- Core EPS
- Earnings per share calculated after excluding certain items to reflect the company’s ongoing operating performance.
- Constant Exchange Rate (CER)
- A method of reporting financial results that removes the impact of currency fluctuations.
- Phase III readout
- Results from the final, large‑scale clinical trial phase before a drug can seek regulatory approval.
- Pipeline
- The set of drugs a company is developing, from early research through to potential market launch.
- EPS Learn
- Earnings per share — profit for one share of the company, in dollars.
- Revenue
- Sales — money the company took in before costs.